A phase I study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2013
At a glance
- Drugs Sirolimus (Primary) ; Bevacizumab
- Indications Liver cancer
- Focus Adverse reactions; Biomarker
- 07 Jun 2017 Biomarkers information updated
- 14 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 May 2007 New trial record.